William Hildebrand to Antibodies, Monoclonal
This is a "connection" page, showing publications William Hildebrand has written about Antibodies, Monoclonal.
Connection Strength
1.071
-
Expanding the targets available to therapeutic antibodies via novel disease-specific markers. Int Rev Immunol. 2011 Oct-Dec; 30(5-6):312-27.
Score: 0.323
-
TCR-like biomolecules target peptide/MHC Class I complexes on the surface of infected and cancerous cells. Int Rev Immunol. 2011 Oct-Dec; 30(5-6):328-40.
Score: 0.323
-
Immunodominant West Nile Virus T Cell Epitopes Are Fewer in Number and Fashionably Late. J Immunol. 2016 05 15; 196(10):4263-73.
Score: 0.111
-
Human Leukocyte Antigen-Presented Macrophage Migration Inhibitory Factor Is a Surface Biomarker and Potential Therapeutic Target for Ovarian Cancer. Mol Cancer Ther. 2016 Feb; 15(2):313-22.
Score: 0.108
-
An HLA-presented fragment of macrophage migration inhibitory factor is a therapeutic target for invasive breast cancer. J Immunol. 2011 Jun 01; 186(11):6607-16.
Score: 0.078
-
Direct discovery and validation of a peptide/MHC epitope expressed in primary human breast cancer cells using a TCRm monoclonal antibody with profound antitumor properties. Cancer Immunol Immunother. 2010 Apr; 59(4):563-73.
Score: 0.070
-
Development and implementation of a direct detection, quantitation and validation system for class I MHC self-peptide epitopes. J Immunol Methods. 2007 Jan 10; 318(1-2):47-58.
Score: 0.057